HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Damage to multicellular human H-2 glioma spheroids incubated with LAK cells: an ultrastructural study.

Abstract
Local brain tumor therapy using lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) has not proved to be effective in preliminary clinical trials. One obstacle to effective use of this therapy is ignorance about the events that follow contact of the LAK cells with glioma tissue. We used multicellular spheroids grown from human glioma cell lines as targets to study, in vitro, the effect of LAK cells against three-dimensional glioma tissue. Here we describe the ultrastructural changes in spheroids of H-2 glioma cells incubated in pellets of LAK cells for up to 24 hours. In H-2 spheroids, cellular damage was not restricted to the effector cell-target cell (effector-target) contact; it extended farther, at least partly because of nonspecific changes in the spheroid micromilieu. Formation of cytoplasmic blebs, a characteristic effect of T cells, natural killer cells, and LAK cells on single target cells, also occurs in H-2 spheroids, and it is not limited to the effector-target contact area either. These findings suggest that LAK cells release membrane-damaging agents that remain active outside the effector-target area, in the micromilieu of H-2 spheroid tissue.
AuthorsJ Jääskeläinen, E Lehtonen, P Heikkilä, P Kalliomäki, T Timonen
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 82 Issue 6 Pg. 497-501 (Mar 21 1990) ISSN: 0027-8874 [Print] United States
PMID2313722 (Publication Type: Journal Article)
Topics
  • Cytotoxicity, Immunologic
  • Dose-Response Relationship, Immunologic
  • Glioma (immunology, ultrastructure)
  • Humans
  • Immunity, Cellular
  • In Vitro Techniques
  • Killer Cells, Lymphokine-Activated (immunology)
  • Microscopy, Electron
  • Microscopy, Electron, Scanning
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: